Abstract
In this triple analysis report BioSeeker Group has analyzed three major and
intertwined areas of cancer R&D, Melanoma Therapeutics, Antibodies and
Vaccines in Oncology, which are all subjects to an extensive number of
innovative drug candidates. This extensive 380+ pages report compiles and
analyzes in parallel the progress concerning drug development and competitive
situation in the three mentioned key oncology areas. The report will not only
provide a framework but also a careful identification and evaluation of drug
candidates, technologies and competitors
Melanoma drug development has and will continue to have a strong focus on
target therapy such as vaccines, monoclonal antibodies, dendritic cells, and
gene therapy. In recent years, immunologic strategies including tumor vaccine
and adjuvant therapy with interferon-alfa have been attempted to improve
survival of patients with more advanced malignant melanoma. Another emerging
strategy in anticancer therapy is the targeting of chemotherapy resistance by
overcoming the antiapoptosis mechanisms of cancer cells
Melanoma Highlights:
- Disease overview, including incidence, unmet needs, risk factors,
screening and diagnosis
- Analysis of current treatment and key therapeutic strategies, including
surgery, immunotherapy, vaccines and combination therapies
- Includes product profiles of key drugs by class.
- Progress analysis of on more than 55 pipeline products, including emerging
and hot pre-clinical data, discontinued projects, clinical trial information,
commercial potential and limiting factors.
Competitive landscape analysis, including extensive lay-out of competitors
with collaborations, licensing, M&A etc, major highlights, trends and company
profiles on more than 50 of the most important companies in melanoma.
Among the targeted therapies for cancer, immunotherapy is probably the most
versatile treatment strategy for the eradication of tumors, metastatic spread
or not. Main strategies of cancer immunotherapy aim at exploiting the
therapeutic potential of tumor-specific antibodies and cellular immune
effector mechanisms (vaccines).
Immunotherapy in Oncology Highlights:
- In-depth competitive landscape assessment of the cancer immunotherapy
market place; Including more than 200 immunotherapy drugs and pharmaceutical
companies
- Thorough review of tumor antigen discovery, immunomodulating strategies
and adjuvants
- Thorough review of antibody and vaccine delivery and technologies
surrounding it - The next generation
- Progress analysis of six major cancer vaccine indications and late stage
antibody development projects, including players, drugs, clinical progress and
pitfalls
| 
View Cart
